The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2016:

• 33 negotiations are currently underway with 8 files (including 2 biosimilars) added since the last update of May 31, 2016:
  • Abilify (aripiprazole): used for the treatment of schizophrenia and related psychotic disorders
  • Basaglar (insulin glargine): used to treat type 1 and 2 diabetes mellitus
  • Entresto (sacubitril/valsartan): used to treat heart failure
  • Grastofil (filgrastim): used to treat neutropenia
  • Jakavi (ruxolitinib): used to treat polycythemia vera
  • Metoject (methotrexate): used to treat rheumatoid arthritis
  • Plegridy (PegIFN beta-1a): used to treat relapsing-remitting multiple sclerosis (RRMS)
  • Strensiq (asfotase alfa): used to treat hypophosphatasia

• 109 joint negotiations have been completed with 2 files completed since the last update of May 31,  2016:
  • Cosentyx (secukinumab): used to treat moderate to severe plaque psoriasis
  • Zydelig (idelalisib): used to treat relapsed chronic lymphocytic leukemia (CLL)

• 38 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with 1 new file added since the last update of May 31, 2016:
  • Jinarc (tolvaptan): used to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD)

• 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of May 31, 2016.

For more information, please consult the pCPA’s website.